DB:CX5P

Stock Analysis Report

Executive Summary

CytRx Corporation, a biopharmaceutical company, engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has CytRx's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CX5P has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

CX5P

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-72.3%

CX5P

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: CX5P underperformed the German Biotechs industry which returned 5.3% over the past year.

Return vs Market: CX5P underperformed the German Market which returned 17.1% over the past year.


Shareholder returns

CX5PIndustryMarket
7 Day0%11.2%7.3%
30 Day0%-5.3%-17.9%
90 Day4.2%-21.9%-25.8%
1 Year-72.3%-72.3%-4.9%-5.1%-15.1%-17.7%
3 Year-89.9%-89.9%17.7%16.5%-18.7%-25.6%
5 Year-97.9%-97.9%-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is CytRx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CytRx undervalued compared to its fair value and its price relative to the market?

0.56x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CX5P's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CX5P's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CX5P is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CX5P is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CX5P's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CX5P is good value based on its PB Ratio (0.6x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is CytRx forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

58.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CytRx has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has CytRx performed over the past 5 years?

24.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CX5P is currently unprofitable.

Growing Profit Margin: CX5P is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CX5P is unprofitable, but has reduced losses over the past 5 years at a rate of 24.7% per year.

Accelerating Growth: Unable to compare CX5P's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CX5P is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: CX5P has a negative Return on Equity (-37.28%), as it is currently unprofitable.


Next Steps

Financial Health

How is CytRx's financial position?


Financial Position Analysis

Short Term Liabilities: CX5P's short term assets ($19.9M) exceed its short term liabilities ($1.9M).

Long Term Liabilities: CX5P has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: CX5P is debt free.

Reducing Debt: CX5P had no debt 5 years ago.


Balance Sheet

Inventory Level: CX5P has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CX5P's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CX5P has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CX5P has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 58.9% each year.


Next Steps

Dividend

What is CytRx's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CX5P's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CX5P's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CX5P's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CX5P's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CX5P's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.2yrs

Average management tenure


CEO

Steve Kriegsman (77yo)

17.25s

Tenure

US$1,013,700

Compensation

Mr. Steven A. Kriegsman, also known as Steve, founded The Kriegsman Group in 1992 and serves as its President. Mr. Kriegsman also founded Kriegsman Capital Group LLC and has been its President since 1989.  ...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD1.01M) is above average for companies of similar size in the German market ($USD425.50K).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Steven Kriegsman
Chairman of the Board & CEO17.25yrsUS$1.01m2.6% $239.1k
John Caloz
CFO & Treasurer10.75yrsUS$500.00k0.0022% $206.8
Felix Kratz
Senior Vice President5.58yrsUS$302.00kno data
Eric Curtis
President & COO1.42yrsno datano data

8.2yrs

Average Tenure

61.5yo

Average Age

Experienced Management: CX5P's management team is seasoned and experienced (8.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Steven Kriegsman
Chairman of the Board & CEO17.25yrsUS$1.01m2.6% $239.1k
Louis Ignarro
Lead Director2.67yrsUS$124.00k0.0065% $597.6
Earl Brien
Director2.83yrsUS$99.80k0.030% $2.8k
Joel Caldwell
Director2.25yrsUS$109.20kno data

2.8yrs

Average Tenure

70.5yo

Average Age

Experienced Board: CX5P's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.7%.


Top Shareholders

Company Information

CytRx Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CytRx Corporation
  • Ticker: CX5P
  • Exchange: DB
  • Founded: 1985
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$10.091m
  • Listing Market Cap: US$9.193m
  • Shares outstanding: 33.64m
  • Website: https://www.cytrx.com

Number of Employees


Location

  • CytRx Corporation
  • 11726 San Vicente Boulevard
  • Suite 650
  • Los Angeles
  • California
  • 90049
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYTROTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 1986
CX5PDB (Deutsche Boerse AG)YesCommon StockDEEURNov 1986
0I5RLSE (London Stock Exchange)YesCommon StockGBUSDNov 1986

Biography

CytRx Corporation, a biopharmaceutical company, engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company’s lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides albumin companion diagnostic for cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/09 20:30
End of Day Share Price2019/07/12 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.